Polycyclo Ring System Having The Five-membered Hetero Ring As One Of The Cyclos Patents (Class 514/410)
  • Patent number: 10729135
    Abstract: The present invention is directed to a method of controlling a pest comprising applying an effective amount of one or more terpendoles to the pest or an area in need of pest control. The present invention is further directed to a method of controlling a pest comprising applying an effective amount of one or more compounds having the following chemical structure to the pest or an area in need of pest control.
    Type: Grant
    Filed: September 25, 2018
    Date of Patent: August 4, 2020
    Assignee: VALENT BIOSCIENCES LLC
    Inventors: Deanna Branscome, Daniel F. Heiman, Jose Maria Sanchez Lopez, Joseph H. Lustig, Gary T. Wang
  • Patent number: 10722582
    Abstract: The present application relates generally to a method and a composition matter that provides a rapid and potent antimicrobial photodynamic inactivation (aPDI) of pathogenic bacteria that express high-affinity cell-surface hemin receptors (CSHRs) using Ga(III)-protoporphyrins IX (GaPpIX or Ga-PpIX). The invention provides an effective treatment option for infections of skin or body cavities that are accessible to visible-light irradiation, such as a handheld LED array emitting visible light (405 nm), especially for infections caused by Staphylococcus aureus, Methicillin-resistant Staphylococcus aureus (MRSA), pathogenic staphylococci, Streptococcus mutans, S. pneumoniae, S. pyogenes, streptococci, corynebacteria, mycobacteria, and Bacillus anthracis.
    Type: Grant
    Filed: March 29, 2019
    Date of Patent: July 28, 2020
    Assignee: Purdue Research Foundation
    Inventors: Alexander Wei, Ana Victoria Morales-de-Echegaray
  • Patent number: 10688049
    Abstract: A process is described for the preparation of freeze-dried pharmaceutical compositions of mitomycin C, which are characterized by high stability and can be rapidly reconstituted to form solutions.
    Type: Grant
    Filed: October 16, 2014
    Date of Patent: June 23, 2020
    Assignee: MEDAC GESELLSCHAFT FÜR KLINISCHE SPEZIALPRÄPARATE MBH
    Inventors: Sonja Schuldt-Lieb, Sebastian Bialleck, Ingo Guhde, Michaela Rehberg
  • Patent number: 10684274
    Abstract: The invention relates to compounds and methods for restoring or preserving cholesterol efflux in a cell infected with Human Immunodeficiency Virus (HIV) by preventing or decreasing an interaction between Negative Regulatory Factor (Nef) protein and Calnexin protein, and methods for screening for such compounds.
    Type: Grant
    Filed: January 12, 2017
    Date of Patent: June 16, 2020
    Assignee: THE GEORGE WASHINGTON UNIVERSITY, A CONGRESSIONLLY CHARTERED NOT-FOR-PROFIT CORPORATION
    Inventors: Alexei Adzhubei, Michael Bukrinsky, Ruth Hunegnaw
  • Patent number: 10662155
    Abstract: Disclosed are methods for the preparation of Tecovirimat for the treatment or prophylaxis of viral infections and diseases associated therewith, particularly those viral infections and associated diseases caused by the orthopoxvirus.
    Type: Grant
    Filed: November 9, 2018
    Date of Patent: May 26, 2020
    Assignee: Siga Technologies Inc.
    Inventor: Dongcheng Dai
  • Patent number: 10508082
    Abstract: The application relates to a compound of Formula (I): which modulates the activity of ALK or SRPK, a pharmaceutical composition comprising the compound, and a method of treating or preventing a disease in which ALK or SRPK plays a role.
    Type: Grant
    Filed: September 23, 2016
    Date of Patent: December 17, 2019
    Assignee: Dana-Farber Cancer Institute, Inc.
    Inventors: John Hatcher, Nathanael S. Gray, Hwan Geun Choi, Pasi Janne, Tinghu Zhang
  • Patent number: 10487055
    Abstract: The invention provides bridged diindole compounds, related pharmaceutical compositions and methods of use thereof, for the prevention, palliation and/or treatment of nervous system disorders.
    Type: Grant
    Filed: June 1, 2017
    Date of Patent: November 26, 2019
    Assignee: Rhode Island Board of Education
    Inventors: Kyle Robert Scully, Roberta S. King, David R. Worthen
  • Patent number: 10344267
    Abstract: Compounds and methods are providing involving RebH variants with improved properties. directed evolution based on random mutagenesis was employed to generate a series of RebH variants. RebH variants with improved thermostability and increased activity at elevated temperatures were generated.
    Type: Grant
    Filed: November 26, 2014
    Date of Patent: July 9, 2019
    Assignee: The University of Chicago
    Inventors: Jared C. Lewis, Catherine Poor, Mary Andorfer, James Payne
  • Patent number: 10261085
    Abstract: This document provides methods and materials involved in treating bladder cancer. This document also provides methods and materials involved in identifying bladder cancer patients likely or unlikely to respond to treatment (e.g., BCG therapy).
    Type: Grant
    Filed: December 13, 2016
    Date of Patent: April 16, 2019
    Assignee: Mayo Foundation for Medical Education and Research
    Inventors: Nancy A. Lee, James J. Lee, Erik P. Castle, Rafael Nunez Nateras
  • Patent number: 10253033
    Abstract: A method of making a bacteriochlorin is carried out by condensing a pair of compounds of Formula II to produce the bacteriochlorin, wherein R is an acetal or aldehyde group. The condensing may be carried out in an organic solvent, preferably in the presence of an acid. The bacteriochlorins are useful for a variety of purposes such as active agents in photodynamic therapy, luminescent compounds in flow cytometry, solar cells, light harvesting arrays, and molecular memory devices.
    Type: Grant
    Filed: November 20, 2017
    Date of Patent: April 9, 2019
    Assignee: North Carolina State University
    Inventors: Han-Je Kim, Jonathan S. Lindsey
  • Patent number: 10048207
    Abstract: Provided are compositions, kits, and methods for detecting a vesicle comprising a membrane permeable marker that is converted into a detectable marker inside the vesicle.
    Type: Grant
    Filed: April 4, 2013
    Date of Patent: August 14, 2018
    Assignee: SAMSUNG ELECTRONICS CO., LTD.
    Inventors: Hyun-ju Kang, Ye-ryoung Yong, Myo-yong Lee
  • Patent number: 10029115
    Abstract: A system for treatment of tumors includes a vessel having a photosensitizing agent therein, a delivery device for communicating the photosensitizing agent from the vessel to tumor tissue, a light source for radiating the tumor tissue after the delivery device has delivered the photosensitizing agent to the tumor tissue, a catheter having at least one inflatable balloon positioned thereon, and a fluid source that repeatedly inflates and at least partially deflates the inflatable balloon such that a resecting outer surface of the balloon contacts the radiated tumor tissue and resects the tissue.
    Type: Grant
    Filed: September 16, 2014
    Date of Patent: July 24, 2018
    Assignee: Sanovas Intellectual Property, LLC
    Inventors: Lawrence J. Gerrans, Erhan H. Gunday
  • Patent number: 9872903
    Abstract: A targeting thymidine kinase photosensitizer and pharmaceutical composition and use for cancer treatment thereof is provided, which improves the selectivity of photosensitizers to tumor cells, has better tolerance, can reach maximum blood concentration in 24 hours, has a bigger conjugated system, a longer absorption wavelength and an advantage in treating depth tumors; the wavelength area does not need to consume much energy of a light-output device and even LEDs can be used, which render PDT more practical and economical. The targeting thymidine kinase photosensitizer can be used for diagnosis and for treating prostatic carcinoma via the guidance of fluorescence imaging. The pharmaceutical composition uses a combination of a chemotherapeutic agent and the targeting thymidine kinase photosensitizer, which further improves the therapeutic effect of the PDT method, expands the application range for tumors and has good effects on metastatic tumors as well.
    Type: Grant
    Filed: November 2, 2012
    Date of Patent: January 23, 2018
    Assignee: ZHEJIANG HISUN PHARMACEUTICAL CO., LTD
    Inventors: Ravindra K Pandey, Yihui Chen, Hua Bai, Zhenliang Chen
  • Patent number: 9822123
    Abstract: A method of making a bacteriochlorin is carried out by condensing a pair of compounds of Formula II to produce the bacteriochlorin, wherein R is an acetal or aldehyde group. The condensing may be carried out in an organic solvent, preferably in the presence of an acid. The bacteriochlorins are useful for a variety of purposes such as active agents in photodynamic therapy, luminescent compounds in flow cytometry, solar cells, light harvesting arrays, and molecular memory devices.
    Type: Grant
    Filed: January 23, 2014
    Date of Patent: November 21, 2017
    Assignee: North Carolina State University
    Inventors: Han-Je Kim, Jonathan S. Lindsey
  • Patent number: 9733187
    Abstract: The method of detecting bladder cancer by optical analysis of bodily fluids utilizes optical techniques to determine a concentration of porphyrin in a patient's bodily fluid sample. The patient is administered 5-aminolevulinic acid and, approximately eight hours later, a bodily fluid sample is collected from the patient, and this bodily fluid sample is optically analyzed to measure a concentration of porphyrin therein. Optical analysis is preferably performed by laser-induced fluorescence spectroscopy. If the measured concentration of porphyrin is approximately three times a pre-determined porphyrin concentration for a healthy person of the same age as the patient, then the patient is diagnosed with bladder cancer.
    Type: Grant
    Filed: March 6, 2015
    Date of Patent: August 15, 2017
    Assignee: King Saud University
    Inventors: Vadivel Masilamani, Mohamad Saleh Alsalhi, Karim Hamda Farhat, Danny Monther Rabah, Saradh Prasad, Sandhanasamy Devanesan
  • Patent number: 9724537
    Abstract: There are provided an apparatus and a method for blocking abnormal conduction in the cardiac muscle using a photodynamic therapy or for treating arrhythmia. There is provided a catheter ablation apparatus for the treatment of arrhythmia using a photodynamic therapy, comprising a catheter leading a photoradiation unit to an abnormal electrical conduction site or a hyperexcitability occurring site in the cardiac muscle of a test subject in which a photosensitizer is present by administering the photosensitizer beforehand and which causes arrhythmia, means for generating a light ray with which the abnormal electrical conduction site or the hyperexcitability occurring site is irradiated, and means for transmitting the light ray to the abnormal electrical conduction site or the hyperexcitability occurring site, wherein the photosensitizer used is a water-soluble chlorine-based photosensitizer and the light ray used is a light ray having an excitation wavelength equal to that of the photosensitizer.
    Type: Grant
    Filed: January 7, 2015
    Date of Patent: August 8, 2017
    Assignee: KEIO UNIVERSITY
    Inventors: Tsunenori Arai, Shuntaro Hosokawa
  • Patent number: 9670486
    Abstract: In one aspect, the invention is directed to a method of characterizing a mechanism of action of a combination of agents. The method comprises contacting a plurality of populations of cells with a combination of agents to be assessed, wherein each population of cells have one gene of interest targeted by a small hairpin RNA (shRNA) and wherein the gene of interest regulates cell death and a plurality of genes that regulate cell death are targeted in the plurality of populations of cells. A responsiveness of each population of cells to the combination of agents is determined, thereby obtaining an shRNA signature of the combination of agents so as to identify one or more genes that mediate a response to the combination of agents, thereby characterizing the mechanism of action of the combination of agents.
    Type: Grant
    Filed: December 16, 2011
    Date of Patent: June 6, 2017
    Assignee: Massachusetts Institute of Technology
    Inventors: Justin Pritchard, Douglas A. Lauffenburger, Michael Hemann
  • Patent number: 9572834
    Abstract: In some embodiments, the present invention provides methods of treating oxidative stress in a subject by administering a therapeutic composition to the subject. In some embodiments, the therapeutic composition comprises a carbon nanomaterial with anti-oxidant activity. In some embodiments, the anti-oxidant activity of the carbon nanomaterial corresponds to ORAC values between about 200 to about 15,000. In some embodiments, the administered carbon nanomaterials include at least one of single-walled nanotubes, double-walled nanotubes, triple-walled nanotubes, multi-walled nanotubes, ultra-short nanotubes, graphene, graphene nanoribbons, graphite, graphite oxide nanoribbons, carbon black, oxidized carbon black, hydrophilic carbon clusters, and combinations thereof. In some embodiments, the carbon nanomaterial is an ultra-short single-walled nanotube that is functionalized with a plurality of solubilizing groups.
    Type: Grant
    Filed: April 26, 2012
    Date of Patent: February 21, 2017
    Assignees: WILLIAM MARSH RICE UNIVERSITY, BAYLOR COLLEGE OF MEDICINE
    Inventors: James M. Tour, Jacob Berlin, Daniela Marcano, Ashley Leonard, Thomas A. Kent, Robia G. Pautler, Brittany Bitner, Taeko Inoue
  • Patent number: 9505771
    Abstract: A stable micronized monoclinic form of asenapine maleate is described, which comprises 5% by weight or less of orthorhombic form or any other crystalline form of asenapine maleate, wherein the asenapine maleate has a particle size distribution characterized by a d90 equal to or below 40 ?m. Processes for preparing the stable micronized monoclinic form of asenapine maleate are also described. Formula (I).
    Type: Grant
    Filed: May 18, 2012
    Date of Patent: November 29, 2016
    Assignee: Laboratories Lesvi S.L.
    Inventors: Agusti Bertran, Josep Terradas
  • Patent number: 9481662
    Abstract: There are provided, inter alia, derivatives of seriniquinone and methods useful for the treatment of cancer, and in particular treatment of melanoma and prostate cancer.
    Type: Grant
    Filed: January 27, 2015
    Date of Patent: November 1, 2016
    Assignee: THE REGENTS OF THE UNIVERSITY OF CALIFORNIA
    Inventors: William Fenical, Paul R. Jensen, James J. La Clair, Lynnie Trzoss, Takashi Fukuda
  • Patent number: 9457083
    Abstract: The present invention relates to a liposome composition comprising 0.001 to 5% by weight of conjugate of lysophophatidylcholine and chlorin e6, 1 to 10% by weight of sucrose laurate, 0.1 to 5% by weight of sodium stearoyl glutamate, 1 to 10% by weight of PEG-5 rapeseed sterol, 1 to 20% by weight of medium-chain triglyceride, 1 to 10% by weight of vegetable oil, 0.1 to 5% by weight of sodium deoxycholate, 3 to 10% by weight of glycerin and the balance of water, and a skin care composition comprising the same. The liposome composition of the present invention is very effective in the treatment of acne.
    Type: Grant
    Filed: January 22, 2015
    Date of Patent: October 4, 2016
    Assignee: H&A PHARMACHEM CO., LTD
    Inventors: Hong Geun Ji, Hyo Gyoung Yu, Young Rong Woo, Jeong Dong Kim, Se Hee Jo, Kun Na, Hyung Park
  • Patent number: 9447109
    Abstract: Disclosed is asenapine phosphate of formula (I) and its enantiomer (I) which can be used to prepare asenapine maleate. Further disclosed is a monoclinic crystalline form of asenapine maleate.
    Type: Grant
    Filed: April 30, 2012
    Date of Patent: September 20, 2016
    Assignee: OLON S.P.A.
    Inventors: Samuele Frigoli, Davide Longoni, Tamara Danelli, Marco Alpegiani
  • Patent number: 9399756
    Abstract: Methods of stimulating an increase in biomass by stimulating the growth, lifespan and/or reproduction of organisms such as fungi, algae, plants, and other aquatic organisms are provided by applying an effective amount of functionalized fullerenes. For example, polyhydroxy fullerenes are effective at low levels of promoting the increase in biomass.
    Type: Grant
    Filed: April 7, 2011
    Date of Patent: July 26, 2016
    Assignee: UNIVERSITY OF FLORIDA RESEARCH FOUNDATION, INC.
    Inventors: Jie Gao, Vijay Krishna, Wei Bai, Benjamin L. Koopman, Brij M. Moudgil, Paul Anthony Indeglia, Kevin Michael Folta, Angelina Tsenova Georgieva
  • Patent number: 9365591
    Abstract: Provided herein are novel fluoroergoline derivatives and compositions thereof. In other embodiments, provided herein are methods of treatment, prevention, or amelioration of a variety of medical disorders such as, for example, migraine using the compounds and compositions disclosed herein. In still other embodiments, provided herein are methods of agonizing receptors such as, for example, the 5-HT1D and/or the 5-HT1B receptor, without agonizing the 5-HT2B receptor using the compounds and compositions disclosed herein. In still other embodiments, provided herein are methods of antagonizing or inhibiting activity at receptors such as, for example, the adrenergic alpha2A and/or the alpha2B receptors using the compounds and compositions disclosed herein.
    Type: Grant
    Filed: August 28, 2015
    Date of Patent: June 14, 2016
    Assignee: MAP Pharmaceuticals, Inc.
    Inventors: Robert O. Cook, Jian Zhang, Thomas A. Armer
  • Patent number: 9340548
    Abstract: The invention relates to compounds of Formula (I) and pharmaceutically acceptable salts thereof, wherein R1, R2, R3 and R4 are defined herein, and their use for the treatment of hepatitis C viral infection.
    Type: Grant
    Filed: August 22, 2012
    Date of Patent: May 17, 2016
    Assignee: Boehringer Ingehleim International GmbH
    Inventors: Christian Brochu, Chantal Grand-Maitre, Marc-Andre Joly, Cyrille Kuhn, Megan Bertrand-Laperle, Marc Pesant
  • Patent number: 9303037
    Abstract: The present invention is directed to novel tetracyclic heteroatom containing derivatives, pharmaceutical compositions containing them, their use in the treatment of disorders mediated by one or more sex steroid hormone receptors and processes for their preparation.
    Type: Grant
    Filed: November 11, 2013
    Date of Patent: April 5, 2016
    Assignee: Janssen Pharmaceutica NV
    Inventors: Zhihua Sui, Xuqing Zhang, Xiaojie Li
  • Patent number: 9303165
    Abstract: Compound of Formula I: are described, along with compositions containing the same and methods of use thereof.
    Type: Grant
    Filed: May 30, 2012
    Date of Patent: April 5, 2016
    Assignee: North Carolina State University
    Inventors: Jonathan S. Lindsey, Michael Krayer
  • Patent number: 9241921
    Abstract: A composition comprising an active ingredient selected from the group of 5-aminolevulinic acid or a pharmaceutically acceptable salt or derivative thereof; and an aqueous carrier comprising at least one absorption enhancer, an anesthetic, hyaluronic acid and at least one acid selected from the group consisting of glycolic acid and lactic acid. The composition is useful in a photodynamic method of treating skin disorders.
    Type: Grant
    Filed: May 2, 2011
    Date of Patent: January 26, 2016
    Inventor: Pankaj Modi
  • Patent number: 9169262
    Abstract: Novel crystalline salts of Asenapine (I) with organic di-acids and tri-acids and to methods of their preparation are disclosed along with related pharmaceutical compositions and methods of treating psychotic diseases or disorders.
    Type: Grant
    Filed: May 15, 2012
    Date of Patent: October 27, 2015
    Assignee: SANDOZ AG
    Inventors: Fritz Blatter, Katharina Reichenbächer
  • Patent number: 9149651
    Abstract: An energy treatment system to treat a patient includes an energy delivery device having a plurality of energy emitters used in combination with an energy activatable drug. A mask can be used to define a treatment area. Energy from the energy emitters passes through an optical window of the mask to activate a cosmetically and/or therapeutically effective amount of the activatable drug at the target site to bring about a desired change of tissue, for example, to reduce visibility of one or more blood vessels, while energy from the energy emitters directed outside of the target site is blocked by the mask.
    Type: Grant
    Filed: January 8, 2008
    Date of Patent: October 6, 2015
    Assignee: PURDUE PHARMACEUTICAL PRODUCTS L.P.
    Inventors: Llew Keltner, James C. Chen
  • Patent number: 9115138
    Abstract: Various porphyrin compounds comprising one or more pyridone moieties, intermediates thereof, compositions thereof, and, methods of making and using thereof.
    Type: Grant
    Filed: May 21, 2013
    Date of Patent: August 25, 2015
    Inventors: John L. Lombardi, Chuchawin Changtong
  • Patent number: 9108916
    Abstract: Compounds of the general structural formula (I) and (II) and use of the compounds and salts and hydrates thereof, as therapeutic agents are disclosed. Treatable diseases and conditions include cancers, inflammatory diseases and conditions, and immunodeficiency diseases. (I), (II).
    Type: Grant
    Filed: April 1, 2014
    Date of Patent: August 18, 2015
    Assignee: Incuron, LLC
    Inventors: John Tucker, Sergey Sviridov, Leonid Brodsky, Catherine Burkhart, Andrei Purmal, Katerina Gurova, Andrei Gudkov
  • Patent number: 9089530
    Abstract: Provided is an antimalarial drug which is useful for prevention and treatment of infectious diseases caused by malaria parasites. A preventive and/or therapeutic agent for malaria, which contains, as an active ingredient, 5-aminolevulinic acid (ALA), a derivative thereof, or a pharmacologically acceptable salt thereof, is used.
    Type: Grant
    Filed: May 18, 2011
    Date of Patent: July 28, 2015
    Assignees: SBI Pharmaceuticals Co., Ltd., The University of Tokyo
    Inventors: Tohru Tanaka, Satofumi Kawata, Takeo Kohda, Motowo Nakajima, Kiyoshi Kita
  • Patent number: 9090590
    Abstract: The invention relates to compounds of the formula (1), to a method for producing compounds of the formula (1), to the use of the compounds in electronic devices and to electronic devices containing compounds according to formula (1), preferably as electron transport materials, as matrix materials, as electron blocking materials or as emitting materials.
    Type: Grant
    Filed: October 14, 2010
    Date of Patent: July 28, 2015
    Assignee: Merck Patent GmbH
    Inventors: Christof Pflumm, Arne Buesing, Amir Hossain Parham, Rocco Fortte, Holger Heil, Philipp Stoessel, Teresa Mujica-Fernaud
  • Patent number: 9061009
    Abstract: Methods of treating metabolic stress disorders are disclosed that include administering to a subject a therapeutically effective amount of a composition that specifically inhibits the expression or activity of a mixed lineage kinase (MLK). Also disclosed are methods of identifying candidate compounds for treatment of metabolic stress disorders and methods of diagnosing metabolic stress disorders.
    Type: Grant
    Filed: June 9, 2008
    Date of Patent: June 23, 2015
    Assignee: University of Massachusetts
    Inventors: Roger J. Davis, Anja Jaeschke
  • Patent number: 9045415
    Abstract: Peptides and compounds are provided that function as EWS-FLI1 protein inhibitors. The peptides and compounds have utility in the treatment of Ewing's sarcoma family of tumors. Also provided are methods of preparing the compounds and assays for identifying inhibitors of EWS-FLI1 protein.
    Type: Grant
    Filed: March 9, 2010
    Date of Patent: June 2, 2015
    Assignee: Georgetown University
    Inventors: Jeffrey A. Toretsky, Aykut Üren, Milton Lang Brown, Yali Kong
  • Publication number: 20150148314
    Abstract: There are provided, inter alia, derivatives of seriniquinone and methods useful for the treatment of cancer, and in particular treatment of melanoma and prostate cancer.
    Type: Application
    Filed: January 27, 2015
    Publication date: May 28, 2015
    Inventors: William Fenical, Paul R. Jensen, James J. La Clair, Lynnie Trzoss, Takashi Fukuda
  • Publication number: 20150140122
    Abstract: The invention relates to methods for detecting inactivation of the DNA Homologous Recombination pathway in a patient, and in particular for detecting BRCA1 inactivation.
    Type: Application
    Filed: June 6, 2013
    Publication date: May 21, 2015
    Applicant: INSERM (Institut National de la Sante et de la Rec herche)
    Inventors: Marc-Henri Stern, Elodie Manie, Tatiana Popova
  • Publication number: 20150141478
    Abstract: The present invention relates to a series of new drugs which refer to chemical series capable of catalyzing the decomposition of H2O2 to generate singlet oxygen (1O2). The drugs relate to therapeutic mechanisms, different from traditional photodynamic therapy, in which the specific affinity of photofrin to focus, such as tumors, vascular plaques and skin diseases is utilized. The activation of photofrin is carried out by specific protein binding or by electron beam, x-ray, r-ray, or other means, to focus, catalyze the decomposition reaction of H2O2 to generate 1O2 in the focus, 1O2 further induces apoptosis and necrosis of cells with pathological changes. The drugs are useful in tumors, vascular plaques and skin diseases, and cosmetic effects on skin are prompted. The drugs obtained via the screening and studying of the present invention are used for chemodynamic therapy (CDT), or for radiochemodynamic therapy (RCDT) carried out via radioactive rays.
    Type: Application
    Filed: January 29, 2015
    Publication date: May 21, 2015
    Inventors: Jun Zeng, Qiyin Sun
  • Patent number: 9026203
    Abstract: The invention relates to pharmaceutically acceptable salts of amphiphilic photosensitizing agents which have a water solubility of at least 0.5 mg/ml and to their use in methods of photochemical internalization. Such salts may be formed from a pharmaceutically acceptable base, for example an organic amine such as an amino alcohol, or from a pharmaceutically acceptable acid, for example a sulphonic acid or a sulphonic acid derivative. Due to their increased water solubility, such salts are particularly suitable for use in the preparation of parenteral pharmaceutical preparations, e.g. for use as solutions for injection or infusion.
    Type: Grant
    Filed: August 16, 2010
    Date of Patent: May 5, 2015
    Assignee: PCI Biotech AS
    Inventors: Jo Klaveness, Anders Hogset
  • Publication number: 20150119383
    Abstract: Embodiments disclosed herein generally relate to acamprosate formulations, methods of use of the formulations, to methods of using the formulations in combination with at least one other medication, and to combination products and compositions comprising the formulations and at least one other medication, such as neuroleptic (antipsychotic) and/or antidepressant drugs.
    Type: Application
    Filed: June 5, 2014
    Publication date: April 30, 2015
    Inventors: Barry S. Fogel, William D. Kerns, Kei-Lai Fong, San-Laung Chow, Edward Lin, David Wong
  • Patent number: 9012441
    Abstract: Compounds of formula I: or salts thereof are disclosed. Also disclosed are pharmaceutical compositions comprising a compound of formula I, processes for preparing compounds of formula I, intermediates useful for preparing compounds of formula I and therapeutic methods for treating a Retroviridae viral infection including an infection caused by the HIV virus.
    Type: Grant
    Filed: January 9, 2014
    Date of Patent: April 21, 2015
    Assignee: Gilead Sciences, Inc.
    Inventors: Steven S. Bondy, Carina E. Cannizzaro, Chien-Hung Chou, Yunfeng Eric Hu, John O. Link, Qi Liu, Scott D. Schroeder, Winston C. Tse, Jennifer R. Zhang
  • Patent number: 8999296
    Abstract: Provided is a sensitizing detection agent of an oral or intravenous administration type which enables the detection of bladder cancer with a higher sensitivity without causing pain to the patient. A sensitizing detection agent for bladder cancer comprising 5-aminolevulinic acid (ALA), a derivative thereof, or a salt of these is orally or intravenously administered, and a video camera system is inserted via the urethra and a blue light at 380-440 nm is irradiated to observe the red fluorescent part. Further, VLD-M1 is inserted and a blue light at 405 nm is irradiated to observe fluorescence intensity (relative intensity) of the red light part. For oral administration, 20 mg/kg (maximum of 1 g) of ALA is dissolved in 50 mL of a 5% glucose solution prior to the administration.
    Type: Grant
    Filed: April 21, 2009
    Date of Patent: April 7, 2015
    Assignees: Kochi University, SBI Pharmaceuticals Co., Ltd.
    Inventors: Keiji Inoue, Masahiro Ishizuka, Tohru Tanaka
  • Patent number: 9000027
    Abstract: The invention describes methods that are useful for treating cancer by administering a Chk1 inhibitor which can induce apoptosis in p53-defective cells when combined with a chemotherapy and/or radiotherapy. Methods for screening candidates for a Chk1 inhibitor-based cancer treatment regimen are also described.
    Type: Grant
    Filed: February 4, 2009
    Date of Patent: April 7, 2015
    Assignee: Dana-Farber Cancer Institute, Inc.
    Inventors: A. Thomas Look, Samuel Sidi
  • Publication number: 20150094351
    Abstract: The use, as a dermatological or cosmetic medicament, of compounds capable of transiently interacting with the AhR receptor (aryl hydrocarbon receptor) as agents for modulating skin functions such as sebaceous function, skin healing, skin atropy termed “dermatoporosis”, estrogen deprivation and defense against infection, without inducing other toxic effects of the TCDD type. The compounds that interact with the AhR receptor are chosen in that they have a metabolism favorable to the dissociation of these effects, in particular by virtue of in situ production from a precursor and/or metabolization modulated in situ.
    Type: Application
    Filed: November 7, 2014
    Publication date: April 2, 2015
    Applicant: THESAN PHARMACEUTICALS, INC.
    Inventor: Jean Hilaire SAURAT
  • Patent number: 8993614
    Abstract: There are provided compounds of the formula wherein X, Y, Z, R1, R2, R3 and R4 are as described herein and enantiomers and pharmaceutically acceptable salts and esters thereof. The compounds are useful as anticancer agents.
    Type: Grant
    Filed: March 5, 2013
    Date of Patent: March 31, 2015
    Assignee: F. Hoffmann-La Roche AG
    Inventors: David Joseph Bartkovitz, Xin-Jie Chu, Binh Thanh Vu, Chunlin Zhao, Daniel Fishlock
  • Publication number: 20150087685
    Abstract: Methods and devices related to the treatment of diseases using phototherapy are described. Some embodiments provide an organic light-emitting diode device, such as a light-emitting device for phototherapy, comprising Ring System 1, Ring System 2, Ring System 3, Ring System 4 or Ring System 5. Methods of treating disease with phototherapy are also described.
    Type: Application
    Filed: April 12, 2013
    Publication date: March 26, 2015
    Inventors: Sazzadur Rahman Khan, Shijun Zheng, Sheng Li, Amane Mochizuki, Keisaku Okada
  • Publication number: 20150079111
    Abstract: Mechanisms for complications of renal failure and processes for treating the same are disclosed. They include contacting a biological fluid (e.g. blood) with a filter body, the filter body having immobilized thereon either a CD36 receptor or a CD36 receptor fragment or a SCARB1 receptor or a SCARB1 receptor fragment, the blood having a reduced quantity of oxidatively modified proteins after contacting the filter body. They also include administering an antagonist drug to a patient that blocks the binding activity of the RAGE receptor or the CD36 receptor or the SCARB1 receptor. Diagnostic methods are also provided.
    Type: Application
    Filed: June 5, 2013
    Publication date: March 19, 2015
    Inventor: Jonas AXELSSON
  • Patent number: 8968715
    Abstract: The invention is generally related to the field of photodynamic therapy by use of photosensitizers and stabilized formulations of the photosensitizers. These formulations may be used to deliver a photosensitizer as a pharmaceutical, agricultural, or industrial agent. The photosensitizer containing formulations and compositions of the invention comprise one or more block copolymers. Furthermore, the invention relates to processes for the production of, and application of, said formulations and compositions as photosensitizer drug delivery systems.
    Type: Grant
    Filed: November 17, 2006
    Date of Patent: March 3, 2015
    Assignee: The University of British Columbia
    Inventors: Rubinah K. Chowdhary, David Dolphin
  • Publication number: 20150057326
    Abstract: A method of synthesizing cycloalkanyl[b]indoles, as well as related cycloalkanyl[b]benzofurans and cycloalkanyl[b]benzothiophenes is provided. The method is a single, multicomponent reaction that combines (1) an indole, benzofuran, or benzothiopene, (2) an aldehyde, ketone, or ketal, and (3) a diene in the presence of an acid, in particular a Ga(III) or In(III) salt. Compositions and methods of using these compounds to stimulate secretion and/or production of glucagon-like peptide-1 or inhibit the activity of Calcitonin Gene-Related Peptide receptor are also provided.
    Type: Application
    Filed: November 10, 2014
    Publication date: February 26, 2015
    Applicant: Trustees of Dartmouth College
    Inventor: Jimmy Wu